143 related articles for article (PubMed ID: 15167918)
1. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia.
Virchis A; Hughes C; Berney S
Hematol J; 2004; 5(3):281-2. PubMed ID: 15167918
[No Abstract] [Full Text] [Related]
2. Use of recombinant activated factor VII in a Jehovah's Witness patient.
Hsieh A; Cheong I
Am J Emerg Med; 2007 Nov; 25(9):1085.e1-2. PubMed ID: 18022514
[No Abstract] [Full Text] [Related]
3. Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient.
Veneri D; Franchini M
Am J Hematol; 2005 Aug; 79(4):344-5. PubMed ID: 16044447
[No Abstract] [Full Text] [Related]
4. The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
Waddington DP; McAuley FT; Hanley JP; Summerfield GP
Br J Haematol; 2002 Oct; 119(1):286-8. PubMed ID: 12358947
[No Abstract] [Full Text] [Related]
5. Recombinant factor VIIa for major obstetric haemorrhage in a Jehovah's Witness.
Laird R; Carabine U
Int J Obstet Anesth; 2008 Apr; 17(2):193-4. PubMed ID: 18308545
[No Abstract] [Full Text] [Related]
6. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
Sniecinski RM; Chen EP; Levy JH; Szlam F; Tanaka KA
Anesth Analg; 2007 Apr; 104(4):763-5. PubMed ID: 17377078
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation.
Jabbour N; Gagandeep S; Peilin AC; Boland B; Mateo R; Genyk Y; Selby R; Zeger G
Am Surg; 2005 Feb; 71(2):175-9. PubMed ID: 16022020
[TBL] [Abstract][Full Text] [Related]
8. Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa.
Mindikoglu AL; Anantharaju A; George M; Leone N; Bejna J; Van Thiel DH
Hepatogastroenterology; 2003; 50(53):1697-9. PubMed ID: 14571820
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa in massive postpartum haemorrhage.
Karalapillai D; Popham P
Int J Obstet Anesth; 2007 Jan; 16(1):29-34. PubMed ID: 17125989
[TBL] [Abstract][Full Text] [Related]
10. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
Tanaka KA; Waly AA; Cooper WA; Levy JH
Anesthesiology; 2003 Jun; 98(6):1513-5. PubMed ID: 12766668
[No Abstract] [Full Text] [Related]
11. Preferences of Jehovah's Witnesses regarding haematological supports in an obstetric setting: experience of a single university teaching hospital.
Husarova V; Donnelly G; Doolan A; Garstka M; Ni Ainle F; McCaul C
Int J Obstet Anesth; 2016 Feb; 25():53-7. PubMed ID: 26597403
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma.
Goldberg R; Drummond KJ
J Clin Neurosci; 2008 Oct; 15(10):1164-6. PubMed ID: 17702584
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding.
Kandane-Rathnayake RK; Isbister JP; Zatta AJ; Aoki NJ; Cameron P; Phillips LE;
ANZ J Surg; 2013 Mar; 83(3):155-60. PubMed ID: 23035873
[TBL] [Abstract][Full Text] [Related]
14. Rectal amputation sparing by haemostatic therapy with recombinant factor VIIa in a patient with cytomegalovirus-related colitis.
Girardis M; Marietta M; Busani S; Codeluppi M; Villa E; Pasetto A
Thromb Haemost; 2006 Mar; 95(3):579-80. PubMed ID: 16525592
[No Abstract] [Full Text] [Related]
15. Mortality risk stratification in severely anaemic Jehovah's Witness patients.
Beliaev AM; Marshall RJ; Smith W; Windsor JA
Intern Med J; 2012 Mar; 42(3):e1-3. PubMed ID: 22432994
[TBL] [Abstract][Full Text] [Related]
16. Administration of four-factor prothrombin complex concentrate for a life-threatening bleed in a Jehovah's Witness patient.
Cole JL; McLeod ND
Blood Coagul Fibrinolysis; 2018 Jan; 29(1):120-122. PubMed ID: 28938310
[TBL] [Abstract][Full Text] [Related]
17. Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa.
Arab TS; Al-Wazzan AB; Maslow K
J Obstet Gynaecol Can; 2010 Oct; 32(10):984-7. PubMed ID: 21176309
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
Majumdar G; Savidge GF
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
[TBL] [Abstract][Full Text] [Related]
19. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia.
Wróbel G; Dobaczewski G; Patkowski D; Sokół A; Grotthus E
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):729-30. PubMed ID: 16933258
[TBL] [Abstract][Full Text] [Related]
20. Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness.
Anton N; Hitzler JK; Kavanagh BP
Br J Haematol; 2002 Sep; 118(4):1183-6. PubMed ID: 12199805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
